

# Sofosbuvir

**Catalog No: tcsc0554**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 500mg

**Size:** 1g



## Specifications

**CAS No:**

1190307-88-0

**Formula:**

$C_{22}H_{29}FN_3O_9P$

**Pathway:**

Anti-infection

**Target:**

HCV

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 100 mg/mL (188.88 mM; Need ultrasonic)

**Alternative Names:**

PSI-7977;GS 7977

**Observed Molecular Weight:**


529.45

**Product Description**

Sofosbuvir (PSI-7977) is an **HCV** RNA replication inhibitor with an **EC<sub>50</sub>** of 92 nM.

IC50 & Target: EC50: 92±5 nM (HCV)<sup>[1]</sup>

**In Vitro:** When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976<sup>[1]</sup>. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1)-, 1a (H77)-, and 2a (JFH-1)-derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC<sub>50</sub>s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC<sub>50</sub>=4.7 nM). Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC<sub>90</sub> values of 0.42 and 7.8 μM, respectively<sup>[2]</sup>. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC<sub>90</sub> values 0.42 μM<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!